MedTrace Logo

A Study to Evaluate the Efficacy and Safety of AD-224

NCT06291207 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 252

Last updated 2025-02-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of AD-224

Conditions

  • Hypertension,Essential

Interventions

DRUG

AD-224A

PO, Once daily, 8weeks

DRUG

AD-224B

PO, Once daily, 8weeks

DRUG

AD-224C

PO, Once daily, 8weeks

DRUG

Placebo of AD-224A

PO, Once daily, 8weeks

DRUG

Placebo of AD-224B

PO, Once daily, 8weeks

DRUG

Placebo of AD-224C

PO, Once daily, 8weeks

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Principal Investigators

  • InHo Chae, M.D., Ph.D · Seoul National University Bundang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-15
Primary Completion
2025-07-31
Completion
2025-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06291207 on ClinicalTrials.gov